Title: Radioimmunotherapy of Infection with 213Bi-Labeled Antibodies
Volume: 1
Issue: 3
Author(s): Ekaterina Dadachova
Affiliation:
Keywords:
Bismuth-213, radioimmunotherapy, fungal infection, bacterial infection, viral infection, apoptosis, radiobiological mechanisms, inflammation
Abstract: Bismuth-213 (213Bi) (physical half-life 46 min) is a beta-emitter (97%) and an alpha-emitter (3%) which decays to short lived alpha-emitter Polonium-213 and could therefore be used as a generator of alpha particles with the energy of around 8 MeV. 213Bi has been successfully used during the last decade in both clinical and pre-clinical work for radioimmunotherapy (RIT) of cancer with 213Bi-labeled monoclonal antibodies (mAbs). RIT has been proposed as a novel techonology for treatment of infectious diseases. 213Bi-labeled mAbs have been successfully used for treatment of experimental fungal, bacterial and viral infections with transient or none hematologic toxicity. The mechanisms of RIT of infection with 213Bi-labeled mAbs include “direct” killing of cells and induction of apoptosis. RIT results in decrease of inflammation in infected organs. Among the delivery vehicles for RIT of infection whole IgG1 mAbs seem to be the most suitable in terms of the highest uptake in the target organs and the lowest – in normal tissues. RIT with alpha-emitter 213Bi involves the application of established technology developed for the treatment of malignancies to infectious diseases. The development of RIT for infectious diseases is potentially easier than its application to tumor therapy given antigenic and tissue perfusion differences between sites of microbial infection and tumor infiltration. Nevertheless, considerable preclinical and clinical development work is likely to be required to learn how to use RIT for infection optimally.
